<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>12</volume><submitter>Parker K</submitter><pubmed_abstract>The SS18-SSX fusion protein is an oncogenic driver in synovial sarcoma. At the molecular level, SS18-SSX functions as both an activator and a repressor to coordinate transcription of different genes responsible for tumorigenesis. Here, we identify the proto-oncogene &lt;i>FYN&lt;/i> as a new SS18-SSX target gene and examine its relation to synovial sarcoma therapy. FYN is a tyrosine kinase that promotes cancer growth, metastasis and therapeutic resistance, but SS18-SSX appears to negatively regulate &lt;i>FYN&lt;/i> expression in synovial sarcoma cells. Using both genetic and histone deacetylase inhibitor (HDACi)-based pharmacologic approaches, we show that suppression of SS18-SSX leads to &lt;i>FYN&lt;/i> reactivation. In support of this notion, we find that blockade of FYN activity synergistically enhance</pubmed_abstract><journal>Frontiers in cell and developmental biology</journal><pagination>1422452</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11264242</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Combination of HDAC and FYN inhibitors in synovial sarcoma treatment.</pubmed_title><pmcid>PMC11264242</pmcid><pubmed_authors>Anchondo G</pubmed_authors><pubmed_authors>Kondo T</pubmed_authors><pubmed_authors>Parker K</pubmed_authors><pubmed_authors>Zhang Y</pubmed_authors><pubmed_authors>Smith A</pubmed_authors><pubmed_authors>Su L</pubmed_authors><pubmed_authors>Guerrero Pacheco S</pubmed_authors></additional><is_claimable>false</is_claimable><name>Combination of HDAC and FYN inhibitors in synovial sarcoma treatment.</name><description>The SS18-SSX fusion protein is an oncogenic driver in synovial sarcoma. At the molecular level, SS18-SSX functions as both an activator and a repressor to coordinate transcription of different genes responsible for tumorigenesis. Here, we identify the proto-oncogene &lt;i>FYN&lt;/i> as a new SS18-SSX target gene and examine its relation to synovial sarcoma therapy. FYN is a tyrosine kinase that promotes cancer growth, metastasis and therapeutic resistance, but SS18-SSX appears to negatively regulate &lt;i>FYN&lt;/i> expression in synovial sarcoma cells. Using both genetic and histone deacetylase inhibitor (HDACi)-based pharmacologic approaches, we show that suppression of SS18-SSX leads to &lt;i>FYN&lt;/i> reactivation. In support of this notion, we find that blockade of FYN activity synergistically enhance</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024</publication><modification>2025-06-01T01:16:26.572Z</modification><creation>2025-06-01T01:16:26.572Z</creation></dates><accession>S-EPMC11264242</accession><cross_references><pubmed>39045458</pubmed><doi>10.3389/fcell.2024.1422452</doi></cross_references></HashMap>